Medulloblastoma with extensive nodularity (MBEN) is one of the few central nervous system (CNS) tumor entities occurring in infants which is traditionally associated with good to excellent prognosis. Some MBEN, however, have been reported with an unfavorable clinical course. We performed an integrated DNA/RNA-based molecular analysis of a multi-institutional MBEN cohort (n = 41) to identify molecular events which might be responsible for variability in patients' clinical outcomes. RNA sequencing analysis of this MBEN cohort disclosed two clear transcriptome clusters (TCL) of these CNS tumors: "TCL1 MBEN" and "TCL2 MBEN" which were associated with various gene expression signatures, mutational landscapes and, importantly, prognosis. Thus, the clinically unfavorable "TCL1 MBEN" subset revealed transcriptome signatures composed of cancer-associated signaling pathways and disclosed a high frequency of clinically relevant germline PTCH1/SUFU alterations. In contrast, gene expression profiles of tumors from the clinically favorable "TCL2 MBEN" subgroup were associated with activation of various neurometabolic and neurotransmission signaling pathways, and germline SHH-pathway gene mutations were extremely rare in this transcriptome cluster. "TCL2 MBEN" also revealed strong and ubiquitous expression of VSNL1 (visinin-like protein 1) both at the mRNA and protein level, which was correlated with a favorable clinical course. Thus, combining mutational and epigenetic profiling with transcriptome analysis including VSNL1 immunohistochemistry, MBEN patients could be stratified into clinical risk groups of potential value for subsequent treatment planning.
3
MB [10, 16, 17, 25, 39] . Although MBEN has been outlined in the current WHO classification of central nervous system (CNS) tumors as a distinct MB histological variant [25] , DNMB and MBEN are sometimes considered as cognate SHH MB entities. Some MB clinical trials therefore do not separate patients with these histological subtypes, taking into account that event-free survival does not differ significantly between them [14, 16, 17, 19, 30, 32] . MBEN are traditionally associated with good to excellent outcomes, reaching almost 100% overall survival in some series. On the other hand, some tumors with MBEN histology have also been reported to show an unfavorable clinical course [10, 16, 17, 39] . Recently, germline PTCH1/SUFU mutations were identified as molecular hallmarks of MBEN progression, suggesting a clinico-biological heterogeneity of these histologically uniform CNS tumors [1, 5, 9, 11, 16, 17, 41] . We have recently shown that DNMB and MBEN are driven by different transcriptional programs accompanied with variability in their clinical course [17] . Some transcriptional heterogeneity within the MBEN cohort was also suggested, but the limited sample number did not allow for solid conclusions-thus necessitating a more detailed investigation.
In the current study, we performed an integrated DNA/ RNA-based molecular analysis of a large multi-institutional MBEN cohort with patient follow-up data to discover molecular events which might be responsible for variability in MBEN outcomes and which might explain biological mechanisms underlying an aggressive clinical behavior in some cases. Previous experience showed that such integrative molecular approaches are very useful for elaboration of diagnostic and prognostic algorithms for various CNS tumor entities and therefore might be helpful for direct practical application in the clinic [6, 14, 28, 30, 32, 36, 37] .
Materials and methods

Patient population
Tissue and blood samples were obtained from 41 pediatric patients (age 0-16 years) with a histological diagnosis of "medulloblastoma with extensive nodularity" (MBEN) according to the 2016 WHO classification of tumors of the central nervous system (CNS) [10, 16, 17, 25, 26, 39] . All patients were initially diagnosed at the NN Burdenko Neurosurgical Institute (Moscow, Russia), Heidelberg University (Germany), Ospedale Santobono-Pausilipon (Naples, Italy), Bambino Gesù Children's Hospital (Rome, Italy), A. Meyer University Children's Hospital (Florence, Italy), Policlinico Umberto I Università Sapienza (Rome, Italy), Neurology Institute (Vienna, Austria), and Washington University (St Louis, USA). FFPE unstained tumor sections from 16 additional MBEN samples were obtained from various sources for immunohistochemical analysis only. Informed consent was obtained from all patients´ parents or other relatives/ caregivers. This retrospective study was conducted under the auspices of the local Ethics Committees.
DNA and RNA extraction
Representative tissue samples with highest available tumor content were histologically identified, microdissected, and chosen for nucleic acid extraction. DNA and RNA were extracted from formalin-fixed and paraffin-embedded (FFPE) tissue samples using the 
DNA methylation analysis
DNA was analyzed using the Illumina Human Methylation 450 or 850 k/EPIC Bead Chip array as previously described [15] [16] [17] . All DNA methylation analyses were performed in R version 3.3.0 (R Development Core Team) as described [12, 15-17, 28, 30, 36] . Raw signal intensities were obtained from IDAT files using the minfi Bioconductor package version 1.18.2. Each sample was individually normalized by performing a background correction (shifting of the 5% percentile of negative control probe intensities to 0) and a dye-bias correction (scaling of the mean of normalization control probe intensities to 10,000) for both color channels. No further normalization or transformation steps were performed, and standard beta values were used for downstream methylation analyses. The following criteria were applied to filter out probes prone to yield inaccurate methylation levels: removal of probes targeting the X and Y chromosomes (n = 11,551), removal of probes that overlap common SNPs (dbSNP132 Common) within the CpG or the following base (n = 7998), and removal of probes not mapping uniquely to the human reference genome (hg19) (n = 3965). To enable comparability between the Illumina Infinium Human Meth-ylation450 and 850k/EPIC arrays, we removed all probes not represented on the 450k array. In total, 428,799 probes were kept for analysis. For unsupervised hierarchical clustering, we selected the 10,000 most variably methylated probes across the dataset as measured by standard deviation. Samples were clustered using Pearson correlation coefficient as the distance measure and average linkage (x-axis). Methylation probes were reordered by hierarchical clustering using Euclidean distance and average linkage (y-axis). Additional analysis of tumor subgroups was performed using a t-distributed stochastic neighbor embedding (t-SNE)-based approach [15, 28, 36] . This was computed using the R-package R-tsne, version 0.13, with a perplexity of 15 and 20 iterations. Copy number profiles were generated using the 'conumee' package for R [12, 15] . DNA methylation raw data are available on request.
Targeted next-generation sequencing (NGS)
Molecular barcode-indexed ligation-based sequencing libraries were constructed using 200 ng of sheared DNA. Libraries were enriched by hybrid capture with custom biotinylated RNA oligo pools covering exons of 130 cancer-associated genes [16, 35, 36] . Paired-end sequencing was performed using the NextSeq 500 (Illumina). Sequence data were mapped to the reference human genome using the Burrows-Wheeler Aligner [35] and were processed using the publicly available SAM tools. Only variants annotated as "exonic" or "splicing" were included, "intergenic" and other untranslated regions were excluded. Recurrent gene mutations of PTCH1, SUFU, and SMO were also assessed with residual DNA from the same pool used for sequencing by polymerase chain reaction followed by direct Sanger sequencing of the corresponding exons. Next-generation sequencing raw data are available on request.
RNA sequencing
RNA sequencing of 41 MBEN samples for which RNA of sufficient quality and quantity was available (see above) was performed on a NextSeq 500 (Illumina) as previously described [17, 36, 38] . The reads were aligned to hg19 reference using STAR version 2.5.2b and for each sample, gene expression was quantified by the feature counts module of the Subread package version 1.4.6 using Gencode version 19 annotations and considering uniquely mapped reads only [3, 8, 22] . To identify potential low-quality or outlier samples, quality control and multi-sample comparisons were done using Qualimap version 2.2.1 [3] . An unsupervised tumor sample comparison was performed with principal component analysis, t-distributed stochastic neighbor embedding, and hierarchical clustering based on the selection of the top 1000 and 500 most variable genes with log2 RPKM gene expression normalization. Subgroupspecific differential gene expression analysis was performed by comparing one molecular class against the other using the DESeq2 R package (adjusted p < 0.05). RNA sequencing raw data are available on request. Gene ontology analysis was done using ClueGO (Cytoscape) by combining the top 250 specifically expressed genes in the individual molecular classes, with visualization using Cytoscape version 3.4 [3] . Fusion discovery was done based on RNA sequencing data as described before [17, 27, 29, 38] . Levels of mRNA for selected candidate genes (TaqMan Gene Expression assays for FZD8, KCNT1, KCNC1, VSNL1, ZNF217, SNORD115 and SNORD114; all Applied Biosystems) were also comparatively measured using a quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR) as described [17] .
Immunohistochemistry with visinin-like 1 protein (VSNL1) antibody
Immunohistochemistry (IHC) was conducted on 4-μm-thick formalin-fixed, paraffin-embedded (FFPE) tissue sections mounted on adhesive slides followed by drying at 80 °C for 15 min. For IHC analysis of visinin-like 1 protein (VSNL1), a monoclonal antibody (OTI4A6, #MA5-26516, Thermo Fisher Scientific Inc.) was applied. IHC was performed with an automated immunostainer (Benchmark; Ventana XT) using antigen retrieval protocol CC1 and a working antibody dilution of 1:100 with incubation at 37 °C for 32 min.
Statistics
The distributions of overall survival (OS) and progression-free survival (PFS) were calculated according to the Kaplan-Meier method using the log-rank test for significance. PFS was calculated from the date of diagnosis until tumor recurrence or last contact for patients who were free of disease. OS was calculated from the date of diagnosis until death of the patient from disease or last contact for patients who were still alive. For multivariate analysis, Cox proportional hazards regression models were used. Estimated hazard ratios are provided with 95% confidence intervals and a p value from the Wald test. Tests with a p value below 0.05 were considered significant.
Results
RNA sequencing of MBEN revealed two transcriptome variants
RNA sequencing analysis was performed on 41 MBEN samples, 22 (54%) of which were included in our previous study [17] ("Burdenko set") and 19 (46%) were newly recruited. To stratify the molecular characterization of this MBEN cohort, we performed unsupervised hierarchical clustering ( Fig. 1a ), principal component analysis (PCA; Fig. 1b ) and t-distributed stochastic neighbor embedding (t-SNE; Fig. 1c ) analysis based on the top 500 high-variance genes. All methods indicated that the expression signatures of the 41 MBEN could be subdivided clearly into two transcriptome clusters (TCL) which contained 22 ("TCL1 MBEN") and 19 ("TCL2 MBEN") samples, respectively. These two clusters remained stable when we used differing amounts of variably expressed genes [100, 250 and 1000 (not shown)] thus confirming that expression profiling data are reliable to discriminate these transcriptomic MBEN variants. The ratio of cases obtained from the "old Burdenko" and newly recruited cohorts was similar within both subgroups (12 vs. 10; for "TCL1" (55%/45%) and 11 vs. 8; for "TCL2" (58%/42%), respectively) thus excluding any source-generated batch effect.
Comparing expression levels, we detected 5370 genes and processed pseudogenes differentially regulated between these MBEN transcriptome subgroups (Online Resource Supplementary Tables 1 and 2). The selected set of the top most confident 40 genes differentially expressed between "TCL1" and "TCL2" MBEN subgroups allowed for a clear discrimination ( Fig. 2a ). We performed quantitative reverse transcription real-time PCR (qRT-PCR) validation for five selected genes: two from "TCL1 MBEN" (ZNF217 and FZD8) and three from "TCL2 MBEN" (VSNL1, KCNT1 and KCNC1). We also added to the gene set for qRT-PCR analysis two probes of SNORD family genes (SNORD114-2 and 115-12), because most of the genes from this snoRNA pool (n = 43) were significantly upregulated in "TCL2 MBEN" (Online Resource Supplementary Fig. 1 ). Consistent with the RNA sequencing experiments, the 12 RNA samples from "TCL2 MBEN" displayed statistically significant higher expression levels of all five putative marker genes (Online Resource Supplementary Fig. 2 ) as compared to eight tumors from "TCL1 MBEN" (Mann-Whitney U test, P < 0.01). Conversely, the "TCL1 MBEN" cohort showed higher ZNF217 and FZD8 expression measured by qRT-PCR as compared to "TCL2 MBEN" (Mann-Whitney U test, P < 0.01).
To delineate characteristic signaling patterns for each of these transcriptome-derived MBEN subgroups, we performed pathway identification using gene ontology analysis ( Fig. 2b ; Online Resource Supplementary Tables 3 and 4 ). The transcriptome signature of the "TCL1 MBEN" subgroup was characterized by genes involved in DNA replication, RNA transport, cell cycle activation, p53 signaling, viral carcinogenesis and various cancer-associated pathways (colorectal, prostate, thyroid, and basal cell carcinomas). In contrast, the "TCL2 MBEN" subgroup was enriched with gene sets associated with neuronal function, synaptic transmission (GABAergic, glutamatergic, dopaminergic, and cholinergic), neuroendocrine secretion, muscle contraction and platelet activation.
Gene fusion transcripts were analyzed by various algorithms (as described previously) [17] , and confirmed with direct RNA sequencing. Nevertheless, only a few and nonrecurrent gene fusions were detected (Online Resource Supplementary Table 5 ), and these were not associated with any particular MBEN transcriptome cluster.
To confirm the existence and stability of the identified MBEN transcriptome variants, and also to exclude a possible batch effect, we performed unsupervised clustering, PCA and tSNE analyses with the MBEN RNA sequencing data together with data generated for two other SHH MB histomolecular variants-DNMB (n = 50) and large-cell SHH MB with TP53 mutation (n = 11)-thus covering most of the spectrum of SHH-associated MB. Even in this enlarged SHH MB dataset, the "TCL1 MBEN" and "TCL2 MBEN" subgroups remained stable and clustered separately, with the exception of three "TCL1 MBEN" samples that were distributed among the DNMB cohort (Online Resource Supplementary Fig. 3 ). Notably, some DNMB RNA profiles clustered together with those generated for SHH TP53 MB, thus hinting on a transcriptional overlap within these SHH MB variants and supporting the previously discovered transcriptome heterogeneity of tumors with DNMB histology [17] .
Clinical, pathological, and molecular characteristics of identified MBEN transcriptome variants
Basic clinico-molecular characteristics of all 41 MBEN patients are summarized in Table 1 . There were no differences in patients' age or the male:female ratio between the two MBEN transcriptome subgroups. A similar proportion of patients within these molecular subsets disclosed M2-3 stages at the time of diagnosis, and an equal number of gross total tumor resections was reported. All 41 patients received similar "infant" treatment protocol: HIT-SKK chemotherapy with intraventricular methotrexate (MTX) [20, 31, 33, 34] .
Tumor recurrence was observed in 11 (27%) patients from this MBEN series: seven as a local re-growth and in the other four cases as combined local relapse with spinal metastases (Online Resource Supplementary Figs. 4 and 5 ). Five (12%) patients died from disease progression. Most of the recurrences (10 out of 11; 92%) and all deaths occurred among patients with MBEN from the "TCL1" subgroup. Consequently, progression-free (PFS) and overall survival (OS) were significantly worse for patients harboring tumors , respectively, allows one to discriminate clearly between these tumor cohorts. We also added two genes of SNORD family, most of which were overexpressed in "TCL2 MBEN" variant. b Gene ontology analysis disclosed that "TCL2 MBEN" RNA profiles (blue circles) were associated with neuronal metabolism, synaptic transmission, and neuroendocrine secretion. In contrast, expression profiling signatures of "TCL1 MBEN" (red circles) were characterized by genes involved in DNA replication, cell cycle activation, viral carcinogenesis and various cancer-associated pathways including "basal cell carcinoma" with a "TCL1 MBEN" molecular signature (log-rank test, p < 0.01; Fig. 3a, b) .
Histologically, both outlined MBEN transcriptome variants disclosed a prototypic bi-compartmental microscopic appearance including nodular reticulin-free zones containing cells with various patterns of neuronal maturation, and an interstitial, reticulin-rich component with mitotic activity ( Fig. 3c, d ). There were no histopathological differences between the two MBEN transcriptome variants, and the extent of both nodular and inter-nodular zones did not vary between them. Nuclear expression of NeuN was also identified within the nodular components of both subgroups. MIB1 nuclear expression was observed predominantly in inter-nodular areas, and the median labeling index was similar for both transcriptome variants (18% vs. 17% for "TCL1" and "TCL2" MBEN, respectively; p = 0.71).
To avoid an influence of intra-tumoral MBEN heterogeneity on the sequencing results obtained, we additionally extracted RNA from two distinct tumor regions of 14 samples (five from "TCL1 MBEN" and nine from "TCL2 MBEN", respectively). Data from these analyses confirmed the defined "TCL1/TCL2" MBEN transcriptome dichotomy and showed almost complete similarity of RNA sequencing profiles generated from either a bulk MBEN sample or from two different regions within a single tumor (Online Resource Supplementary Fig. 6 ).
The number of MBEN samples with balanced CNV profiles or showing recurrent chromosomal aberrations (trisomy 2 and loss of 10q) was similar between both transcriptome subgroups. Using targeted NGS, we analyzed tumor and matched normal DNA as described. Single somatic nucleotide variants (SNVs) and small insertions/deletions (indels) were detected across all samples studied. Recurrent alterations affected three "prototypic" SHH-associated genes: PTCH1 (16/41; 39%), SUFU (12/41; 30%), and SMO (6/41; 10%), all of which were mutually exclusive (Online Resource Supplementary Table 6 ). Frequent mutations of KMT2D (also known as MLL2, 12/41; 30%) were also found. All 12 SUFU mutations and 4/16 PTCH1 alterations were also present in matched germline DNA, with most being in the "TCL1 MBEN" cohort (64% of this subgroup harbored a germline alteration vs. 10% for "TCL2 MBEN"; p < 0.01). None of the cases, however, were reported to have recognized apparent clinical patterns of nevoid basal cell carcinoma syndrome (Gorlin syndrome) other than MBEN at the time of diagnosis. The mean number of gene alterations did not differ between the MBEN subgroups: 2.8 ± 1.3 and 3.1 ± 1.3 per tumor, respectively (p = 0.74), but some differences in the mutational landscapes were found (see Fig. 1a ; Table 1 , and Online Resource Supplementary  Table 6 ). SUFU, PTCH1, and KMT2D mutations occurred significantly more often in the "TCL1 MBEN" subgroup. In contrast, all SMO (6), NF1 (5) and PTEN (5) mutations were detected in the "TCL2 MBEN" cohort. Most of the PTCH1 and SUFU mutations in the "TCL1 MBEN" subgroup were multiple, with some showing various combinations of SNVs and/or indels in the same tumor sample, whereas mutations in "TCL2 MBEN" were predominantly either single SNVs or indels (Online Resource Supplementary Figs. 4 and 5 , and Table 6 ). Notably, all PTCH1 alterations in "TCL2 MBEN" were indels, in contrast to the "TCL1 MBEN" cohort where both SNVs and/or indels were detected. The "TCL1 MBEN" PTCH1 alterations predominantly affected exon 18 (5/11; 45%). For 18 MBEN samples, we also extracted and analyzed DNA separately from two different regions of the same tumor. This revealed a complete overlap of mutational profiles between the two regions in all 18 cases.
Correlation between transcriptomic and methylation profiling data
DNA of 41 MBEN samples was analyzed on either Illumina 450k (n = 15) or 850k/EPIC (n = 26) Bead Chip methylation arrays. Unsupervised hierarchical cluster analysis revealed two main epigenetic subgroups (SHH-I and SHH-II; as reported previously [32] ), which, however, did not correspond perfectly with the transcriptome subgroups detected by RNA sequencing (Fig. 4a ). Thus, "TCL1" and "TCL2" MBEN are not as distinct at the epigenetic level, and their profiles were intermixed within both of the previously reported MBEN methylome clusters. These data were also confirmed with t-SNE analysis (Fig. 4b) . While "TCL1 MBEN" samples were more often found to belong to the SHH-I epigenetic cluster (63%) and "TCL2 MBEN" were predominantly found in the SHH-II methylome subgroup Table 2 ), the two techniques clearly do not identify exactly the same subsets within this SHH MB variant. In turn, tSNE analysis of the MBEN RNA sequencing profiles disclosed no discrete separation of tumor samples displaying either an SHH-I or SHH-II methylome signature (Fig. 4c ). In addition, a differential expression analysis between SHH-I and SHH-II MBEN using a q value limit of 0.05 disclosed only 31 differentially expressed genes (Online Resource Supplementary Table 7) , which is in stark contrast to the > 5000 differentially expressed genes identified with the same q value limit between the two identified MBEN transcriptome subgroups.
In contrast to the MBEN transcriptome subgroups, the epigenetic SHH-I and SHH-II subsets ( Table 2) showed differences in the distribution of patient age, male:female ratio, and recurrent CNVs. Also, PTCH1/SUFU germline alterations were distributed evenly between both methylome subgroups. Most importantly, no survival differences were observed between the epigenetic MBEN clusters (Fig. 4d,  e )-suggesting limited clinical relevance of SHH-I and SHH-II MBEN signatures, at least for the patients treated with the HIT-SKK protocol. This is also in line with our data obtained previously for a mixed MBEN/DNMB infant cohort [17] .
Finally, we also directly compared epigenetic and RNA sequencing data, but we did not find any changes in methylation status for the top genes differentially expressed between the "TCL1" and "TCL2" MBEN subgroups-thus suggesting that transcriptional activity of these discriminatory genes is not regulated by DNA methylation status.
Survival analysis
In line with previously reported data [1, 5, 9, 11, 16, 17, 41] , germline PTCH1/SUFU mutations were associated with worse outcomes of MBEN patients. The "TCL2 MBEN" molecular subgroup was found to be associated with favorable patient survival in terms of both PFS and OS (see Fig. 1 ). Upon multivariate analysis, the factor "MBEN transcriptome subgroup" (i.e., "TCL1 MBEN" vs. "TCL2 MBEN") was identified as being independently associated with unfavorable PFS and OS (hazard ratios 5.4 and 3.2 for "TCL1 MBEN" with PFS and OS, respectively; p < 0.01). In addition, we compared survival data of the two outlined MBEN transcriptome variants with those generated for SHH DNMB (n = 64) and SHH LCA MB with TP53 mutation (n = 14) (Online Resource Supplementary Fig. 7 ). We did not find significant differences in survival between "TCL1 MBEN" and DNMB cohorts (p = 0.22 and 0.73 for PFS and OS). However, patients with tumors allocated to "TCL2 MBEN" and SHH TP53 MB molecular subgroups revealed excellent and dismal survival, respectively, thus representing two opposite clinical and biological ends of the SHH MB spectrum.
Immunohistochemistry with visinin-like protein 1 (VSNL1) is a tool for clinically relevant MBEN stratification
Among the genes overexpressed in the clinically favorable "TCL2 MBEN" cohort, we selected VSNL1 (visinin-like-1) for further immunohistochemical (IHC) analysis owing to its high expression level in this tumor set (in comparison to "TCL1 MBEN" cohort, other SHH MB histo-molecular variants and also non-SHH Group 3 and 4 MB molecular subgroups; Fig. 5a ) and availability of a commercially produced antibody. We applied visinin-like protein 1 (VSNL1) monoclonal antibody OTI4A6 to stain all 41 MBEN samples involved in the RNA sequencing experiments and also 16 additional MBEN samples for which transcriptome analysis was not possible due to a lack of high-quality RNA. The three following patterns of cytoplasmic VSNL1 immunostaining were detected: (1) "Diffuse"-tumor sample was entirely and intensively stained, including the nodular MBEN component and collections of cells in inter-nodular regions (Fig. 5b ). (2) "Focal"-patched, single collections of cells with heterogeneous staining intensity were found in the nodular component only (Fig. 5c ). (3) "Negative"-no VSNL1 expression was found throughout the entire MBEN sample (Fig. 5d ). All 19 MBEN samples from the "TCL2 MBEN" set revealed diffuse immunostaining patterns for VSNL1, whereas tumors from the "TCL1 MBEN" set revealed either focal VSNL1 expression (12; 55%) or were completely negative (10; 45%). Among the additional 16 samples from the non-RNA MBEN cohort, six tumors were diffusely positive for VSNL1, six-focally positive, and four remaining samples disclosed no protein expression. We also tested this VSNL1 antibody on 64 DNMB samples, where only four tumors revealed focal immunostaining limited to the "pale islands" (6%). In addition, all 14 samples of SHH MB with TP53 mutations were immunonegative for VSNL1 whereas among 84 Group 3/4 MB, only eight samples (10%) showed scattered cells with VSNL1-positive cytoplasm and four tumors contained small immunostained fragments of entrapped normal cerebellum (5%; Table 3 ). In the entire MBEN set analyzed for VSNL1 expression (n = 57), we compared survival data for tumors with diffuse staining (n = 25) and those with either focal expression (n = 16) or no staining (n = 16). We found that PFS and OS for patients harboring diffusely stained MBEN were significantly better Fig. 4 a Heat map of unsupervised hierarchical cluster analysis across a set of 41 MBEN based on the 10,000 most variable methylation probes; SD > 0.30; beta values: 0-0.5 blue; 0.5-1 red. Two epigenetic MBEN clusters (SHH-I; n = 14 and SHH-II; n = 27) included samples from both transcriptome subgroups ("TCL1"-red boxes; "TCL2" -blue boxes) although in unequal proportions. Two epigenetic MBEN clusters also differ in terms of the patients' age (< 2 years-gray bars and older 2 years-black bars). b Two-dimensional t-distributed stochastic neighbor embedding (tSNE) analysis of MBEN epigenetic profiles revealed no additional tumor subgroups associated with transcriptome subgroups; "TCL1" (red spots) and "TCL2" (blue spots) cohorts were interspersed within SHH-I and SHH-II clusters. c In turn, tSNE analysis of MBEN RNA sequencing profiles disclosed no separate transcriptome subgroups composed of SHH-I (pink spots) and SHH-II (brown spots) methylome profiles with their scattered distribution. d, e Survival analysis for two epigenetic MBEN subgroups revealed no differences in terms of d OS (log rank; p = 0.42) and e PFS (log rank; p = 0.34) ◂ 1 3 ( Fig. 5e, f) . We also analyzed survival for MBEN with focal positivity vs. negativity separately, but we did not find any differences in the clinical outcomes. Thus, these results corroborated the survival data obtained by transcriptome analysis. We therefore consider VSNL1 as an appropriate IHC marker for prognostic stratification of patients with MBEN.
Discussion
Medulloblastoma with extensive nodularity is an infrequent histological variant of infant SHH MB that is traditionally considered as a histo-molecularly homogenous and clinically favorable CNS tumor entity [11] [12] [13] [14] . However, applying a DNA/RNA-based integrated molecular approach on a large MBEN tumor series, we discovered that even such a rare and histologically uniform SHH MB variant may be further stratified in terms of its gene expression signatures. The MBEN cohort disclosed two clear-cut molecular subgroups ("TCL1" and "TCL2") of numerically comparable size which are driven biologically by different transcriptional programs. In turn, this different MBEN biology is associated with divergent clinical course and tumor treatment response. The gene expression signature of the unfavorable "TCL1 MBEN" set was composed of various cancer-associated pathways, possibly explaining their aggressive clinical course. In turn, transcriptional programs of MBEN from the clinically more benign "TCL2" subgroup are associated with signaling pathways involved in activation of various neurometabolic and neurotransmission processes, thus hinting on continued neuronal differentiation of tumor cells and even their possible maturation.
Two epigenetic MBEN subsets (SHH-I and SHH-II) identified by DNA methylation profiling included samples from both transcriptome subgroups (although in unequal proportions) and disclosed no associations with patient outcomes. Moreover, in contrast to transcriptomic MBEN subgroups, the epigenetic clusters were clearly age associated. This is in concordance with suggestions that the epigenetic state of SHH MB is defined at the time of tumor initiation and remains stable, whereas transcriptional programs may evolve during tumor development and progression [13, 17, 28] . Additionally, MBEN transcriptome signatures were not associated with differences in the methylation status of the most differentially expressed genes; therefore, we suggest that the transcriptional diversity of MBEN is not reliably associated with epigenetic dysregulation and might be driven by other molecular mechanisms.
In addition, we identified a conspicuous numerical and structural heterogeneity in the mutational landscapes of the two MBEN transcriptome subgroups. The unfavorable "TCL1 MBEN" cohort was enriched with predominately multiple PTCH1/SUFU mutations, found to already be present in the germline DNA in 60% of patients (although no case with apparent clinical patterns of Gorlin syndrome other than MBEN was identified). This argues for some role of these driving SHH-pathway gene alterations in activation of "cancer-associated" pathways (including "basal cell carcinoma") within "TCL1 MBEN". The distinct biological mechanisms underlying an activation of cancer-specific transcriptional programs in MBEN harboring SHH "mutational complexity" remain to be defined. On the other hand, the identified transcriptome signatures may partly explain the clinically aggressive behavior of SHH MB diagnosed in patients with PTCH1/SUFU germline alterations [1, 5, 9, 11, 41] .
Notably, a number of genes related to the SNORD family were overexpressed in the "TCL2 MBEN" subgroup (see Online Resource Supplementary Fig. 1) . These genes encode a small nucleolar RNA pool (non-coding RNAs) which usually functions in guiding the modification of other non-coding RNAs [4] . It has been shown recently that SNORD115 overexpression induces neuronal differentiation [4] , and upregulation of these genes could therefore play a role in shaping the neuronal-associated "TCL2 MBEN" variant.
VSNL1 was identified among the top upregulated genes in "TCL2 MBEN". The gene product, visinin-like protein 1 (VSNL1), is intensively expressed in cortex neurons and cerebellar granule cells. It associates with membranes in a calcium-dependent manner, thereby modulating neuronal morphology, transmission and plasticity [23] . In colon carcinomas [2] and neuroblastomas [42] , high levels of VSNL1 expression are associated with advanced tumor stages. In contrast, strong and ubiquitous expression of VSNL1 in MBEN (both at gene and protein levels) is correlated with superior outcomes-thus suggesting an upregulation (and intense immunoreactivity) of this neuronal-associated gene as indicator for favorable tumor biological behavior and clinical course. Given the probable prognostic importance of MBEN transcriptome identification, we could recommend VSNL1 IHC as a suitable screening tool, which may even serve as a surrogate marker in the absence of mutational and/or expression analysis. Additionally, evaluation of VSNL1 immunoexpression in small biopsy samples may also have the benefit of discriminating between "TCL2 MBEN" and other MB histologies. In turn, patients with MBEN could be further stratified transcriptionally for a choice of optimal treatment, because HIT-SKK refractory "TCL1 MBEN" may benefit from more intense protocols upfront [18] . Moreover, the identified transcriptional signatures could be considered as potential molecular targets for therapeutic interventions in treatment-resistant MBEN. For the "TCL1 MBEN" cohort (Online Resource Supplementary Fig. 8 ), molecular targeted therapy with inhibitors of ZNF217 and/or PARP4 may be effective, as it has been reported recently for CNS and non-CNS cancers (glioblastoma, breast carcinoma, ovarian cancers) [7, 21, 24] . Further investigation of the clinical and therapeutic relevance of transcriptionally defined MBEN subsets is warranted.
In conclusion, the histologically uniform SHH MB variant designated as "MBEN" exhibits clinically relevant transcriptional heterogeneity separating these tumors into two clear-cut molecular subgroups: clinically aggressive, "cancer-associated TCL1 MBEN" and prognostically favorable, "neuronal-associated TCL2 MBEN". By combining mutational and epigenetic profiling with transcriptome analysis as well as VSNL1 IHC, we could thoroughly stratify MBEN patients into clinical risk groups. The results also testify that such integrated analyses are able to detect clinically relevant markers even for infrequent CNS tumor entities. 
